TheracyteZGU

TheraCyte, Inc.成立于1999年，是Baxter Healthcare Corporation的分拆公司,可提供细胞和基因治疗。TheraCyte™已被用于改善啮齿动物的糖尿病，并通过基因工程技术运送人类生长激素、细胞因子、单克隆抗体和促红细胞生成素等分子。TheraCyte, Inc主要生产细胞封装系统，能够开发基于细胞的治疗产品，用于治疗慢性和复发性疾病，包括糖尿病，感染控制，蛋白质缺乏和免疫紊乱。

TheraCyte, Inc. was founded in 1999 as a spin-out from Baxter Healthcare Corporation. The company deliver scell and gene therapies. TheraCyte™ has been used to correct diabetes in rodents and deliver molecules such as Human Growth Hormone, cytokines, monoclonal antibodies and Erythropoietin using genetically engineered cells. TheraCyte, Inc. manufactures cell encapsulation systems that enable the development of cell-based therapeutic products for treating chronic and recurrent diseases including diabetes, infection control, protein deficiencies, and immunological disorders.

Main product

The Theracyte System 4.5 µL

TheraCyte R&D (sterile) 20.0 µL

TheraCyte R&D (sterile)

Sterile Handling Sleeve (per device)